Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer's Shanghai R&D Site To Serve As R&D Hub For Asia

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Pfizer's Shanghai R&D site will remain the central R&D hub for Asia, Pfizer Head of Asia R&D Steve Yang told PharmAsia News.

You may also be interested in...



Pfizer Korea Builds Up Presence Further In Korea Through Merger With Wyeth Korea

SEOUL - With the Jan. 29 approval of South Korea's Fair Trade Commission, Pfizer swiftly integrated its operations with Wyeth Korea to become one entity Feb. 1

Pfizer Korea Builds Up Presence Further In Korea Through Merger With Wyeth Korea

SEOUL - With the Jan. 29 approval of South Korea's Fair Trade Commission, Pfizer swiftly integrated its operations with Wyeth Korea to become one entity Feb. 1

Pfizer Signs MOU With Wuhan To Establish First R&D Center In Midwest China; Ranks Number One In China

SHANGHAI - Pfizer is expanding its presence in central and Western China, having signed a memorandum of understanding with Wuhan National Bioindustry Base Construction and Management Office Nov. 25 to establish a new R&D site in the National Bioindustry Base Biolake in Wuhan, the province capital of Hubei

Related Content

UsernamePublicRestriction

Register

SC070290

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel